Invernizzi Alessandro, Airaldi Matteo, Cozzi Mariano, Nguyen Vuong, Hashimoto Yohei, Barthelmes Daniel, O'Toole Louise, Ponsioen Theodorus Leonardus, Kusenda Pavol, Lavid Francisco Javier, Jaross Nandor, Gillies Mark, Hunt Adrian
Eye Clinic, Department of Biomedical and Clinical Science "Luigi Sacco", Luigi Sacco Hospital, University of Milan, Milan, Italy.
Discipline of Ophthalmology, Sydney Medical School, The University of Sydney, Save Sight Institute, Sydney, New South Wales, Australia.
Clin Exp Ophthalmol. 2025 May-Jun;53(4):374-383. doi: 10.1111/ceo.14468. Epub 2024 Dec 5.
To assess clinical outcomes of cataract surgery in eyes treated with intravitreal injections for cystoid macular oedema (CMO) secondary to retinal vein occlusions (RVOs).
Eyes receiving intravitreal injections for CMO secondary to RVOs that underwent cataract extraction were identified from the Fight Retinal Blindness! Registry and matched 1:1 by 9 parameters with phakic controls also receiving intravitreal injections for the same condition. VA change at 12 months, central subfield thickness (CST) and injection frequency before and after surgery were compared between the two groups. The effect of baseline features on the final VA including age, CST, treatment frequency among others was tested.
We included 193 eyes that had cataract extraction (exposed) matched with 193 phakic eyes that did not have surgery (matched). VA (95%CI) changed by +9.9 (7, 12.8) letters in exposed eyes versus -2.4 (-4.1, -0.7) letters in matched eyes (p < 0.01). The mean [SD] VA at 12 months was similar in exposed and matched eyes [60.7 (23.0) vs. 61.1 (24.3) letters, respectively, p = 0.81]. The mean [SD] CST was similar between groups before and at surgery, but it was greater in exposed compared with matched eyes [353 (152) vs. 322 (123) μm, respectively, p = 0.03] 12 months after surgery. Exposed eyes received more injections [median (range)] than matched eyes during the 12 months after surgery [5 (3, 7) vs. 4 (1, 6), injections, p < 0.01].
Cataract extraction delivered good visual outcomes in patients treated for CMO secondary to RVOs. More injections were required on average in the 12 months after surgery in eyes undergoing surgery compared to matched controls.
评估玻璃体内注射治疗视网膜静脉阻塞（RVO）继发的黄斑囊样水肿（CMO）的眼睛白内障手术的临床结果。
从“抗击视网膜失明！”登记处识别出接受玻璃体内注射治疗RVO继发CMO并接受白内障摘除术的眼睛，并与同样因该病症接受玻璃体内注射的有晶状体对照眼按9个参数进行1:1匹配。比较两组在术后12个月时的视力变化、中心子野厚度（CST）以及手术前后的注射频率。测试包括年龄、CST、治疗频率等基线特征对最终视力的影响。
我们纳入了193只接受白内障摘除术的眼睛（暴露组），并与193只未进行手术的有晶状体眼睛（匹配组）进行匹配。暴露组眼睛的视力（95%可信区间）提高了9.9（7，12.8）个字母，而匹配组眼睛的视力下降了2.4（-4.1，-0.7）个字母（p<0.01）。术后12个月时，暴露组和匹配组眼睛的平均[标准差]视力相似[分别为60.7（23.0）和61.1（24.3）个字母，p = 0.81]。两组在手术前和手术时的平均[标准差]CST相似，但术后12个月时，暴露组的CST大于匹配组[分别为353（152）和322（123）μm，p = 0.03]。术后12个月内，暴露组眼睛比匹配组眼睛接受了更多的注射[中位数（范围）][5（3，7）次注射对4（1，6）次注射，p<0.01]。
白内障摘除术为治疗RVO继发CMO的患者带来了良好的视觉效果。与匹配的对照组相比，接受手术的眼睛在术后12个月平均需要更多的注射。
